Human b-glucuronidase, due to low intrinsic immunogenicity in humans, is an attractive enzyme for tumor-specific prodrug activation, but its utility is hindered by low activity at physiological pH. Here we describe the development of a high-throughput screening procedure for enzymatic activity based on the stable retention of fluorescent reaction product in mammalian cells expressing properly folded glycoproteins on their surface. We utilized this procedure on error-prone PCR and saturation mutagenesis libraries to isolate b-glucuronidase tetramers that were up to 60-fold more active (k cat /K m ) at pH 7.0 and were up to an order of magnitude more effective at catalyzing the conversion of two structurally disparate glucuronide prodrugs to anticancer agents. The screening procedure described here can facilitate investigation of eukaryotic enzymes requiring posttranslational modifications for biological activity.
INTRODUCTION
Chemotherapy is an important treatment modality for advanced cancers, but systemic toxicity typically limits therapeutic efficacy. Antibody- (Bagshawe et al., 1988; Senter et al., 1988) and gene-directed enzyme prodrug therapy (Chen et al., 1994) (ADEPT and GDEPT) are approaches to increase the therapeutic index of cancer chemotherapy. ADEPT and GDEPT employ antibody-targeted or gene-expressed enzymes to preferentially activate nontoxic antineoplastic drugs at cancer cells, thereby sparing normal tissues from high concentrations of toxic drug. Although microbial and viral enzymes are largely utilized for targeted prodrug activation, the development of strong immune responses against foreign proteins can rapidly hinder therapeutic effectiveness (Napier et al., 2000; Sharma et al., 1992) . The utilization of human enzymes is therefore highly desirable to minimize immune responses and allow multiple rounds of treatment.
b-glucuronidase (bG, EC 3.2.1.31) is an attractive enzyme for ADEPT and GDEPT because both mammalian and bacterial homologs exist. A variety of glucuronide prodrugs have demonstrated impressive antitumor activity in diverse tumor models (de Graaf et al., 2002) . Although many studies have employed Escherichia coli b-glucuronidase (ebG) to activate glucuronide prodrugs at cancer cells because of the high specific activity of the bacterial enzyme (Chen et al., 2001 (Chen et al., , 2007 Cheng et al., 1999b; Wang, 1992) , development of human b-glucuronidase (hbG) therapies is desirable to minimize immune responses in patients. hbG is sequestered in lysosomes and is therefore largely inaccessible to membrane-impermeable glucuronides, minimizing the problem of systemic activation of prodrugs by endogenous enzymes (Cheng et al., 1999a) . As an acid hydrolase, hbG displays maximum activity at pH 4.0, but relatively low activity at neutral pH (Chen et al., 2007) . Translation of glucuronide prodrug therapy to the clinic could be facilitated by generating hbG variants that more efficiently hydrolyze prodrugs under the physiological conditions present in tumors.
The pH profile of enzymes has been altered by substituting specific amino acids that directly (Kim et al., 2006) or indirectly (Makde et al., 2006) contact substrates as well as by changing amino acids on the enzyme surface (Russell and Fersht, 1987) . However, it is difficult to rationally alter the pH profile of an enzyme with retention of catalytic activity. Directed evolution, on the other hand, is an extremely versatile and powerful method to modify protein properties without a priori detailed knowledge of protein structure-function relationships (Kaur and Sharma, 2006) .
Whereas most directed evolution has been performed in bacteria, many eukaryotic proteins require posttranslational modifications such as glycosylation for proper folding and catalytic activity. For example, hbG is expressed as a tetramer composed of four identical monomeric subunits of 629 amino acids, each possessing four N-linked oligosaccharides that are required for proper protein folding (Shipley et al., 1993) . Furthermore, assay of hbG activity at defined pH values is difficult due to cell-tocell variations in lysosomal pH (Anderson and Orci, 1988) . In the present study, we solved these problems by tethering hbG on the surface of mammalian cells to allow assay of properly glycosylated and active enzyme under defined conditions. We show that combination of mammalian cell-surface display with high-throughput flow cytometric sorting allows successful isolation of hbG variants with enhanced activity at neutral pH.
RESULTS

Development of a Mammalian Cell-Surface-Tethered Enzyme Screening System
We tethered human bG (hbG) and mouse bG (mbG) on the surface of mammalian cells by fusing the cDNA for the respective bG genes to the juxtamembrane Ig-like extracellular domain, transmembrane domain, and cytoplasmic tail of murine B7-1 (Chen et al., 2007; Cheng and Roffler, 2008) . mbG was employed for some assays because it displays about 3-fold greater enzymatic activity than hbG at pH 7.0, allowing better sensitivity for initial method development. hbG was stably expressed with retention of enzymatic activity on 3T3 fibroblasts, as determined by surface immunofluorescence staining with a FITC-labeled anti-hbG antibody (7G8-FITC) and by hydrolysis of the substrate ELF-97 b-Dglucuronide to ELF-97 alcohol (Telford et al., 2001 ), a fluorescent product that remained associated with the cells (Figure 1A) . Trypsin proteolysis of cell-surface proteins reduced hbG expression and enzymatic activity in parallel (Figure 1A) , demonstrating that membrane-tethered hbG was responsible for hydrolysis of ELF-97 b-D-glucuronide. The enzymatic activity of membrane-tethered mbG depended on the extracellular pH, allowing convenient control of the enzyme environment ( Figure 1B ). Cells expressing membrane-tethered mbG were clearly distinguishable from wild-type (WT) cells under fluorescence illumination after staining mixed-cell populations with ELF-97 b-D-glucuronide ( Figure 1C ). To determine whether high-throughput flow cytometric sorting of cells based on relative bG activity was feasible, a mixture of WT cells and cells expressing membrane-tethered mbG was first stained with rat anti-mbG antibody followed by goat anti-rat FITC conjugate and then incubated with ELF-97 b-D-glucuronide. Two discrete populations of cells could be clearly separated ( Figure 1D ), demonstrating that enzymatically generated ELF-97 alcohol remained associated with cells expressing membrane-tethered bG during the staining and analysis procedure.
Selection of hbG Variants with Enhanced Activity at Neutral pH
Based on these results, we developed a robust high-throughput fluorescence-activated cell-sorting method to isolate hbG mutants with enhanced activity at neutral pH ( Figure 2A ). We employed error-prone PCR to generate a cDNA library (EP1 library) with a diversity of $5 3 10 6 containing an average of 4.5 amino acid mutations per hbG gene. 3T3 fibroblasts were infected at low MOI (multiplicity of infection; $0.6 cfu/cell) with a VSV-G pseudotyped retroviral virus library to generate $10 7 independent 3T3 clones. After selection in G418, viable cells were stained with 7G8-FITC (anti-hbG-FITC conjugate) and incubated with ELF-97 b-D-glucuronide before they were sorted on a flow cytometer for enhanced bG activity relative to hbG expression levels. The first round of screening was performed at pH 5.0 to enrich for rare cells displaying enhanced bG enzymatic activity at slightly elevated pH ( Figure 2B , left panel). Selected cells ($0.5% of the total cell population) were cultured to expand their numbers and then resorted two additional times after immunofluorescence staining for hbG expression with 7G8-FITC and labeling bG activity with ELF-97 b-D-glucuronide at pH 6.5 to isolate cells displaying enhanced surface enzymatic activity at elevated pH. The sorted population displayed increased enzymatic activity as compared to cells expressing membrane-tethered WT hbG ( Figure 2B , right panel). The sorted population also exhibited enhanced enzyme activity at both pH 5.0 and pH 6.5, indicating that enzyme variants with a broader pH profile can be isolated by applying selection pressure based on reaction pH ( Figure 2C ). Sequencing the hbG gene in 12 individual cell clones revealed multiple mutations. However, all hbG variants had mutations at position 545 (50% T/A and 50% T/S). To determine the effect of amino acid substitutions at position 545 on enzyme activity, the single amino acid mutants T545A (E1-A), T545G (E1-G), T545S (E1-S), and T545Y (E1-Y) were generated and the corresponding enzymes were purified from the culture medium of stably transfected fibroblasts. Assay for enzymatic activity at pH 7.0 with the substrate p-nitrophenol b-D-glucuronide revealed that E1-G and E1-A displayed about 2.5-fold greater activity than WT hbG, E1-S exhibited about 1.5-fold greater activity, and E1-Y was almost inactive (data not shown). Thus, single amino acid changes can affect hbG activity at neutral pH. We employed the E1-G (50%) and E1-A (50%) variants as starting material to generate an error-prone cDNA library (EP2) with 5 3 10 6 members containing an average of 2.6 amino acid mutations per hbG gene. Independent 3T3 clones (5 3 10 7 ) were immunofluorescence stained with 7G8-FITC and reacted with ELF-97 b-D-glucuronide at pH 7.0. Sixteen individual cell clones were isolated after three rounds of sorting and the hbG genes were sequenced. All of the isolated hbG genes possessed identical amino acid substitutions at position 255 (L/Q) and 545 (T/ G) with variable substitutions at other positions. One highactivity variant, termed E2-20, was selected for further examination (Table 1) . To help differentiate between beneficial and null mutations in the hbG variants, hbG cDNA isolated from the sorted EP1 library (30%) was shuffled with the WT hbG gene (70%) to breed out null mutations. The shuffled backcross library was then expressed on 3T3 fibroblasts and screened with 7G8-FITC and ELF-97 b-D-glucuronide at pH 7.0. After one round of flow cytometric sorting, individual cell clones were isolated and the hbG gene was sequenced. Among 13 single-cell clones, amino acid changes at positions 545, 595, and 599 were consistently associated with increased hbG activity at neutral pH values. 
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Saturation Mutagenesis
To further examine the influence of varying the amino acids at positions 545, 595, and 599 on the catalytic activity of hbG, we employed saturation mutagenesis to generate a small library ($10 5 cell clones) covering all possible combinations of amino acids at these three sites. The library was screened by two rounds of cell sorting at pH 7.0. Among 14 single-cell clones displaying high activity, seven different amino acids (all nonnegatively charged) appeared at position 595. Furthermore, 79% of the hbG variants had serine at position 545, and 13 of 14 clones contained amino acids with hydrophobic side groups (28.5% leucine, 28.5% isoleucine, and 43% phenylalanine) at position 599. Two variants (S2 and S28 in Table 1 ) were selected for further analysis. Table 1 summarizes the mutations present in five membranetethered hbG variants which displayed 20-to 115-fold greater enzyme activity than WT hbG for ELF-97 b-D-glucuronide at pH 7.0. The amount of hbG protein expressed by each cell line varied as determined by immunoblot analysis (see Figure S1A available online). There was a strong linear correlation between total hbG expression level (as determined by hbG band intensity on the immunoblot in Figure S1A ) and surface hbG levels, as determined by immunofluorescence staining of hbG followed by flow cytometric analysis ( Figure S1B ). This confirms that immunofluorescence staining allows convenient normalization of enzyme activities for differences in hbG expression levels.
Characterization of bG Variants
To further characterize the hbG variants, we purified soluble hbG enzymes from 3T3 producer cells ( Figure 3A ). The proteins migrated slower than the predicted molecular weight of an hbG monomer due to the presence of N-linked oligosaccharides in the enzyme (Shipley et al., 1993) . hbG displayed maximal activity at pH 4.0 but only 2% of maximal activity at pH 7.0 ( Figure 3B ). The hbG variants exhibited maximal activity at pH 4.5 with relatively broad pH profiles. The kinetic properties of hbG and variants were compared at pH 4.5 and pH 7.0 (Table 2) . Consistent with enhanced enzymatic activity of membrane-tethered hbG, the soluble hbG variants displayed enhanced k cat /K m values at both pH 4.5 and 7.0 ( Figure 3C ). At pH 7.0, E1-S and E1-G displayed k cat /K m values 4-and 10-fold higher than WT hbG, whereas S2, S28, and E2-20 variants displayed 20-to 60-fold enhancements in k cat /K m . Surprisingly, the k cat /K m values of the S2 and E2-20 enzymes at pH 7.0 were about 2-fold greater than the k cat /K m of WT hbG at pH 4.5. The dramatic increases in substrate affinity at acidic and neutral pH explain the overall enhancement in the activities of the hbG variants. Changes in amino acid sequence can adversely affect protein stability (Smith et al., 1997) . However, the enzymatic activity of recombinant hbG variants at pH 7.0 was fully retained for at least 2 weeks 
ND, not determined. a 3T3 fibroblasts expressing membrane-tethered forms of the indicated hbG variants were assayed for hbG surface expression and bG enzymatic activity. Relative activity of membrane-tethered hbGs was calculated as the ratio of FL4 (hbG activity)/FL1 (surface hbG expression) at pH 7.0 and normalized to the FL4/FL1 of WT hbG. The substrate was ELF-97 b-D-glucuronide. 
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Prodrug Activation by hbG Variants
To determine whether the hbG variants also exhibited enhanced activity for anticancer glucuronide prodrugs, we incubated EJ human bladder cancer cells with a constant concentration of HAMG, a nontoxic glucuronide prodrug of p-hydroxyaniline mustard, and graded concentrations of WT or mutant hbGs. All hbG variants hydrolyzed HAMG to cytotoxic drug more efficiently than WT hbG, as demonstrated by enhanced killing of EJ cancer cells ( Figure 4A ). The most active S2 variant was 9-fold more effective than WT hbG (EC 50 = 2.7 versus 24 mg/ml, respectively). A similar result was found for SN-38G, which releases the potent topoisomerase I poison SN38 (Rivory, 1996) upon hydrolysis of the glucuronide moiety ( Figure 4B ). The EC 50 of WT hbG and the S2 variant were 96 and 8.4 ng/ml, respectively, representing an 11-fold improvement in prodrug activation.
DISCUSSION
Alteration of the pH profile of mammalian enzymes by directed evolution has not been described to our knowledge, likely due to the difficulty in establishing an appropriate high-throughput screening system. By combining error-prone PCR with a highthroughput mammalian cell-surface-tethered screening system, we successfully generated hbG variants with enhanced activity over an extended pH range. Importantly, the hbG variants more effectively hydrolyzed two structurally distinct anticancer glucuronide prodrugs at neutral pH. Because previous studies have demonstrated that antibody-hbG immunoenzymes can selectively activate glucuronide prodrugs in tumor xenografts to produce strong antitumor activity (Bosslet et al., 1994) , the hbG variants developed here are anticipated to further increase the therapeutic efficacy of glucuronide prodrug therapy. hbG variants with increased catalytic activity at acidic pH may also be of interest for enzyme replacement therapy of patients suffering from Sly disease (mucopolysaccharidosis type VII), especially for organs, such as the brain, which are difficult to target (Grubb et al., 2008) . ADEPT and GDEPT are being actively developed to increase the therapeutic index of cancer chemotherapy. In ADEPT, an antibody-enzyme conjugate or fusion protein is allowed to accumulate at cancer cells before a relatively nontoxic prodrug is administered. Selective enzymatic hydrolysis of prodrug at cancer cells provides high localized concentrations of cytotoxic agent in tumors (Svensson et al., 1995) . GDEPT is analogous, except that the prodrug-activating enzyme is expressed at the tumor site after viral or nonviral gene transfer of the cancer cells. Most enzymes employed for ADEPT/GDEPT have been derived from microbial or viral sources to increase specificity and reduce systemic prodrug activation, including b-lactamase (Svensson et al., 1995) , carboxypeptidase G2 (Marais et al., 1997) , b-glucuronidase (Wang, 1992) , thymidine kinase (Moolten, 1986) , nitroreductase (Anlezark et al., 1995) , and cytosine deaminase (Mullen et al., 1992) . However, nonhuman enzymes can induce robust immune responses, limiting the number of treatment cycles that can be administrated to patients (Napier et al., 2000) . Several strategies have been investigated to reduce enzyme immunogenicity. Immunosuppressive drugs such as cyclosporine A, cyclophosphamide, and deoxyspergualin can decrease or delay the immune response against foreign proteins . Immunosuppression, however, besides producing toxicity in patients and hindering the development of antitumor immunity generated by prodrug therapy (Chen et al., 2001) , has displayed rather limited suppression of strong antibody responses against bacterial enzymes (Napier et al., 2000; Sharma et al., 1996) . Genetic engineering can be employed to remove immunodominant epitopes from foreign proteins (Spencer et al., 2002) . For example, this technique allowed reduced binding of preexisting antibodies against an immunodominant epitope in carboxypeptidase G2 (Mayer et al., 2004) . However, the large antibody repertoire and the heterogeneity of human MHC molecules make this approach technically challenging. Catalytic antibodies that can selectively hydrolyze anticancer prodrugs have
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Evolution of Membrane-Tethered Human b-Glucuronidase also been developed (Abraham et al., 2007) . This elegant approach can utilize humanized catalytic antibodies to reduce immunogenicity. Highly active catalytic antibodies, however, are rare. Utilization of human enzyme variants with only a few amino acid changes represents an alternative approach for clinical applications.
We successfully isolated hbG variants that displayed greatly enhanced activity at pH 7. Several factors were important for successful identification of mutant enzymes. First, high levels of hbG could be tethered to the surface of 3T3 fibroblasts using membrane-anchoring domains previously developed in our lab (Chou et al., 1999; Liao et al., 2001) , allowing sensitive detection of variants with desirable properties. Second, the high infectability of fibroblasts allowed generation of large libraries (>10 7 clones). Third, expression of hbG on mammalian cells allowed proper glycosylation required for enzymatic activity (Shipley et al., 1993) . Fourth, the reaction pH could be simply controlled by altering the buffer composition because hbG was tethered to the cell surface. Finally, utilization of ELF-97 b-D-glucuronide as the substrate resulted in good retention of fluorescent reaction product in individual clones with little cross contamination of neighboring cells. ELF-97 b-D-glucuronide appears to display similar attributes as ELF-97 phosphate, which possesses high photostability and sensitivity, an unusually large Stokes shift ($170 nm), and precipitates rapidly and remains highly localized to sites of enzyme activity (Cox and Singer, 1999; Paragas et al., 2002; Telford et al., 2001) . By contrast, we observed high background and lack of specificity when we screening cell libraries with fluorescein di-b-D-glucuronide (FDGlcU) or pentafluorobenzoylamino fluorescein-di-b-D-glucuronide (PFBFDGlcU) substrates, as they yield a soluble product (fluorescein) which diffuses rapidly between cells and is therefore not suitable (Lorincz et al., 1999) . Several ELF-97 substrates are commercially available, including ELF-97 N-acetylglucosaminide, ELF-97 palmitate, ELF-97 acetate, and ELF-97 phosphate (Molecular Probes). Simple synthesis of analogous substrates should allow screening by mammalian cell-surface display of almost any eukaryotic enzyme that requires secretory-pathway posttranslational modifications.
Besides allowing good control of reaction conditions, mammalian cell-based surface display combined with quantitative flow cytometric sorting has additional advantages such as (1) high-throughput (10 7 variants can be analyzed per hour), quantitative screening; (2) the presence of an endoplasmic reticulum quality control system to minimize protein-folding errors; (3) efficient surface localization of large oligomeric proteins, such as hbG (a 380 kDa tetramer); and (4) the opportunity to reduce host expression bias by using two-dimensional labeling. For example, we normalized enzyme activity to enzyme surface levels to ensure that observed enhancements were due to altered catalytic activity rather than to cell-to-cell differences in enzyme expression levels. Mammalian surface display thus couples genotype and phenotype while allowing control of selection conditions for evolution of even large oligomeric proteins within a living system. These attributes of mammalian surface display may complement high-throughput screening methods for selection of enzymes based on bacteria (Becker et al., 2007; Olsen et al., 2000; Varadarajan et al., 2005) and yeast (Lipovsek et al., 2007) surface display.
The hbG variants identified in our study include amino acid substitutions at positions 159, 243, 255, and 518 on the surface of hbG and positions 545, 595, and 599 near the catalytic pocket ( Figure 5A ) (Islam et al., 1999) . The catalytic site of hbG is formed by an a/b TIM barrel consisting of eight alternating parallel b strands and a helices. The top of the barrel is formed by loops connecting the C termini of the b strands to the N termini of the a helices. Two of the loops (b4a4 and b7a7) harbor the catalytic residues of hbG (E451 and E540, respectively), in common with many enzymes possessing TIM barrels (Altamirano et al., 2000) . In addition, the b7a7 and b8a8 loops are involved in direct interactions with the corresponding loops in a neighboring monomer that form a large cavity harboring two active sites ( Figure 5B ) (Jain et al., 1996) . T599 in the b8a8 loop interacts with the same amino acid in the neighboring subunit. Single amino acid 
Evolution of Membrane-Tethered Human b-Glucuronidase substitutions in E1-S (T545S) and E1-G (T545G) resulted in substantially enhanced substrate affinity. Interestingly, ebG variants that displayed enhanced catalytic activity against b-D-galactoside substrates also incorporated serine or alanine substitutions at the corresponding threonine (T509 in ebG) (Matsumura and Ellington, 2001) , suggesting that amino acids with smaller side chains might increase the conformational flexibility of the b7a7 loop and alter substrate affinity. Replacement of T599 with hydrophobic amino acids was associated with increased bG activity at neutral pH, suggesting that alterations in monomer interactions may alter substrate binding. The negatively charged glutamic acid residue at position 595 was replaced by neutral or positively charged amino acids in many hbG variants, suggesting that removing a negative charge in the binding pocket might increase enzyme affinity for the negatively charged b-D-glucuronide (pK a $2.8).
Clone E2-20, which includes two mutations on the enzyme surface (L243Q and L255Q), displayed about a 3-fold smaller K m as compared to E1-G, which shares a common mutation of T545G. S2 and S28 variants also have mutations in surface amino acids (V159M and Q518R, respectively). Q518 is present on the a6 helix of the TIM barrel. Substitution of glutamine with arginine is unlikely to disrupt the structure of the a helix, suggesting that the effect of this substitution was mediated by charge effects. Beneficial mutations present on the surface of hbG are difficult to explain, due to their distance from the active site. However, previous studies demonstrated that modifying surface amino acids can shift the pH profile of enzymes (Russell and Fersht, 1987) . Our results confirm that amino acid substitutions which are distant from the catalytic cavity can contribute to enhanced bG activity.
We examined several approaches to increase the activity of hbG at neutral pH during the initial phase of this investigation. In contrast to hbG, ebG catalyzes the hydrolysis of glucuronides with high efficiency at pH 7.0. However, the structure and amino acids in the catalytic pocket of ebG and hbG are nearly identical, hindering rational design of hbG variants by comparison with ebG. On the other hand, molecular modeling indicated that the surface charge of ebG is more negative than hbG ( Figure S2 ). Differences in the surface charge of enzymes may affect the pK a of catalytic amino acids, resulting in alterations in enzymatic pH optima (Russell and Fersht, 1987) . Acid-base catalysis generally requires two carboxy side chains, one which is protonated and the other ionized. In hbG, E451 acts as an acid-base whereas E540 functions as a nucleophile (Islam et al., 1999) . We hypothesized that reducing the surface charge of hbG might increase the pK a of E451, thereby maintaining the carboxy side chain in the acid form at elevated pH levels. Positive and neutral amino acids with side chains predicted to project away from the surface of hbG were therefore substituted with negatively charged amino acids. However, altering the surface charge had minimal effect on the pH optimum of hbG ( Figure S3 ). In addition, all mutants displayed at least 85% reductions in catalytic activity (results not shown). In another approach, we attempted to identify amino acids important in controlling the pH profile of hbG by employing random chimeragenesis on transient templates (RACHITT) to shuffle ebG and hbG genes (Coco et al., 2002) . We could not successfully shuffle these genes, however, likely due to their low overall homology of 50.7%.
In summary, we developed a mammalian cell-surface display approach to evolve hbG variants with enhanced capability to hydrolyze anticancer glucuronide prodrugs at the physiological conditions of the tumor. These hbG variants are anticipated to improve the efficacy of ADEPT and GDEPT and may allow multiple treatment rounds due to their low immunogenicity. Moreover, this technology may be applied on other enzymes and other selection conditions, as mammalian expression libraries of membrane-tethered enzymes allow straightforward in vitro evolution of enzyme properties.
SIGNIFICANCE
Many proteins require posttranslational modifications, such as glycosylation, to correctly fold and display biological activity. Development of high-throughput screening methods for identification of glycoproteins with altered properties will facilitate elucidation of protein structure-function relationships as well as allow isolation of improved proteins for novel biotechnological and medical applications. Toward this goal, we developed a high-throughput screening procedure for enzymatic activity based on tethered enzyme expression and stable retention of fluorescent reaction products in mammalian cells. A key advantage of this methodology is the ability to precisely control screening conditions such as reaction pH. Furthermore, fluorescence-activated cell sorting allows screening of 10 7 enzyme variants per hour and reduces protein expression bias by simple quantitative measurement of surface expression levels. We demonstrated the utility of this screening procedure by isolating variants of human b-glucuronidase, a tetrameric glycoprotein normally present in lysosomes, that displayed significantly enhanced enzymatic activity at pH 7.0. The human b-glucuronidase variants isolated in our study are anticipated to extend the utility of selective cancer therapy by glucuronide prodrug treatment due to low immunogenicity in humans and enhanced catalytic activity at the physiological pH present in human tumors. The screening methodology described here should greatly facilitate investigation and modification of eukaryotic enzymes requiring posttranslational modifications for biological activity.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies ELF-97 alcohol and ELF-97 b-D-glucuronide were from Molecular Probes (Eugene, OR, USA). 4-methylumbelliferyl b-D-glucuronide and CPT-11 were from Sigma-Aldrich (St. Louis, MO, USA). Biotinylated anti-HA antibody was from Vector Laboratories (Burlingame, CA, USA). Rhodamine-conjugated streptavidin and goat anti-rat FITC conjugate were from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Mouse anti-hbG mAb 7G8 and rat antimouse bG (mbG) mAb 7G7 have been described (Chen et al., 2007) . 7G8 was directly labeled with FITC as described (Goding, 1976) . HAMG was synthesized as described (Roffler et al., 1991) . SN-38G was purified by HPLC from the urine of mice treated with CPT-11.
Cells BALB/3T3 fibroblasts (CCL-163; ATCC, Manassas, VA, USA) and CT26 murine colon carcinoma cells (ATCC CRL-2638) were cultured in DMEM (4.5 g/l glucose) supplemented with 10% bovine serum, 2.98 g/l HEPES, 2 g/l NaHCO 3 , 100 U/ml penicillin, and 100 mg/ml streptomycin. EJ human bladder carcinoma
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Evolution of Membrane-Tethered Human b-Glucuronidase cells (Marshall et al., 1977) were cultured in RPMI containing the same supplements. CT26 and EJ cell lines expressing membrane-tethered mbG on their surface have been described (Chen et al., 2007) . All cells were free of mycoplasma as determined by PCR.
Error-Prone PCR A silent mutation was made to change cytosine to guanidine at position 411 of the hbG gene in pLNCX-hbG-eB7 (Chen et al., 2007) to remove an internal SalI site. The resulting vector, pLNCX-hbGs-eB7, was employed as a template for error-prone PCR (Cadwell and Joyce, 1992) using primer P1 (5 0 -TAT GCT GGG GCC CAG CCG GCC-3 0 ), which contains part of the HA epitope at the 5 0 end and an SfiI restriction site at the 3 0 end (underlined), and primer P2 (5 0 -CTG AGA TGA GTT TTT GTT CGT CGA C-3 0 ), which contains part of the myc epitope at the 5 0 end and a SalI restriction site at the 3 0 end (underlined). Mutagenic buffer (8 mM dCTP, 8 mM dTTP, 48 mM MgCl 2 , 5 mM MnCl 2 ) (Matsumura and Ellington, 2001) was added (1.25 or 2.5 ml) to each 50 ml PCR reaction using 5 units Taq polymerase (Takara, Shiga, Japan) for amplification. The PCR product was digested with SfiI and SalI enzymes, ligated into the same sites in pLNCX-hbGs-eB7, and transformed into DH5a competent cells by electroporation. Transformed bacteria were selected on 15 cm carbenicillin-containing LB agar plates for 16 hr at 37 C. Colonies from multiple plates were collected and expanded in carbenicillin-containing LB medium and then amplified by addition of 170 mg/ml chloramphenicol. Plasmid DNA from each library was purified by centrifugation in a CsCl-ethidium bromide density gradient at 60,000 rpm in a Ti 70.1 rotor at 4 C for 24 hr using a Beckman Optima L-90K ultracentrifuge (Beckman Coulter, Fullerton, CA, USA).
Retroviral Transduction
To generate stable cell libraries or His-tagged soluble hbG producer cells, plasmid DNA was cotransfected with pVSV-G (Clontech, Mountain View, CA, USA) into GP293 cells (Clontech) to produce recombinant retroviral particles. Two days after transfection, the culture medium was filtered, mixed with 8 mg/ml polybrene, and added to 3T3 fibroblasts. Stable cell lines were selected in medium containing 0.5 mg/ml G418 (Calbiochem, San Diego, CA, USA). In later experiments, cells were sorted twice each round; cells exhibiting the highest 10% activity were collected and then immediately sorted again to collect the cells displaying the highest 5% activity (representing 0.5% of the total starting population). Double sorting greatly decreased contamination with low-activity cells. The sorted cells were cultured for 4-10 days for sequential rounds of cell sorting or RNA extraction. Flow cytometer data were analyzed using Flowjo (Tree Star, Ashland, OR, USA).
Selection of High-Activity hbG Cells
DNA Shuffling
Variant hbG genes were recovered by RT-PCR from the cells collected after three rounds of FACS. hbG DNA (1 mg) was digested with 0.025 U of DNase I (Takara) in 25 ml of 50 mM Tris-HCl (pH 7.4), 1 mM MgCl 2 for 11 min at 25 C. The reaction was quenched by adding 5 ml of 0.5 M EDTA. DNA fragments ranging from 100 to 300 bases on a 1% agarose gel were reassembled in 35 cycles of primerless PCR (Stemmer, 1994) . The full-length recombinant products, amplified in a standard PCR reaction with P1 and P2 primers, were cloned in pLNCX-hbGs-eB7 to create a new 3T3 cell library.
Saturation Mutagenesis
To generate randomized mutations at amino acid positions 545, 595, and 599 in hbG, two rounds of site-directed mutagenesis were performed using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). All possible amino acids were introduced at amino acid position 545 with primers P3 ( 
Purification of Recombinant hbG Proteins
Recombinant His-tagged hbG was purified from stable 3T3 fibroblast lines as described (Wu et al., 2004) .
Enzyme Assays
The pH-dependent enzyme activities of recombinant hbG variants were measured in triplicate with 0.1 mM ELF-97 b-D-glucuronide at 37 C for 30 min at defined pH ranging from 3 to 10 in bG reaction buffer (50 mM bis-Tris, 50 mM triethanolamine, 100 mM acetic acid, 0.1% BSA). The reaction was quenched by adding an equal volume of stop buffer (2 M Tris-HCl, 0.8 M sodium bicarbonate [pH 8]). The fluorescence of ELF-97 alcohol and 4-methylumbelliferone was measured in a Gemini EM microplate spectrofluorometer (Molecular Devices, Sunnyvale, CA, USA) at excitation/emission wavelengths of 355/555 nm. Kinetic values for hbG substrate hydrolysis were determined by diluting ELF-97 b-D-glucuronide (2 mM) in pH 4.5 or pH 7.0 bG reaction buffer 1:1 with defined concentrations of hbG in 200 ml. Fluorescence was immediately measured under thermal control at 37 C for 8-10 min. The measurement was repeated using the same amount of enzyme for different concentrations of substrate in an optimal range. The acquired readings were converted to product concentration by preestablished standard curves. Double reciprocal plots were used to determine K m and k cat . Kinetic assays were performed at least three times and mean values were calculated. The stability of recombinant hbG variants was assayed by measuring their enzymatic activity at time 0 and again after incubating 5 mg of purified enzyme in PBS (containing 0.5 mg/ml BSA) at 37 C for 14 days. The enzymatic activities of the hbG variants were measured in triplicate with 0.5 mM 4-methylumbelliferyl b-D-glucuronide at 37 C for 15 min at pH 7.0 in bG reaction buffer. The reaction was terminated by adding an equal volume of stop buffer (1 M glycine, 0.5 M sodium bicarbonate [pH 11]) and the fluorescence was measured at excitation/ emission wavelengths of 355/460 nm in a microplate spectrofluorometer. 
Molecular Modeling
To examine potential interactions of ELF-97 b-D-glucuronide with mutated amino acids in hbG variants, the X-ray crystal structure of ebG with glucaro-1,5-lactone in the active site (unpublished data) was employed as a template to position the glucuronide group of ELF-97 b-D-glucuronide. ELF-97 b-D-glucuronide was then docked into the active sites formed by the interaction of two hbG monomers using Molegro 2.2.0 (Aarhus, Denmark).
Statistical Analysis
Statistical significance of differences between mean values was estimated by Excel (Microsoft, Redmond, WA, USA) using the independent t test for unequal variances. P values of less than 0.05 were considered to be statistically significant.
SUPPLEMENTAL DATA
Supplemental Data include three figures and can be found with this article online at http://www.cell.com/chemistry-biology/supplemental/S1074-5521 (08)00411-0/.
